Johnson & Johnson (NYSE:JNJ) Shares Up 2.3% – Still a Buy?

Johnson & Johnson (NYSE:JNJ) rose 2.3% during mid-day trading on Wednesday . The stock traded as high as $218.86 and last traded at $218.5320. Approximately 11,779,885 shares were traded during trading, an increase of 39% from the average daily volume of 8,462,161 shares. The stock had previously closed at $213.65.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Major clinical win — TECVAYLI (teclistamab) Phase 3 MajesTEC-9 topline: monotherapy showed a 71% reduction in risk of progression or death and a 40% reduction in risk of death in patients largely refractory to anti‑CD38 and lenalidomide. That result supports TECVAYLI as a potential new standard of care in earlier relapsed multiple myeloma and meaningfully strengthens J&J’s oncology revenue runway. TECVAYLI MajesTEC-9 Topline Results
• Positive Sentiment: Legal risk reduced — Delaware’s highest court ordered a recalculation/partially overturned a ~$1B damages award tied to the Auris Health transaction, which could lower potential payouts and remove a headline legal overhang for J&J. That decision reduces downside risk to capital and EPS. Delaware court reduces $1B damages
• Neutral Sentiment: MedTech momentum — analysts point to cardiovascular strength and new device rollouts supporting MedTech growth, though China exposure remains a watch item into the next quarter. This is a growth driver but with regional risk to monitor. MedTech growth drivers ahead of Q4
• Neutral Sentiment: Pipeline/clinical disclosures beyond oncology — J&J will present new depression (CAPLYTA, SPRAVATO, seltorexant) analyses at ACNP; useful for longer-term CNS positioning but unlikely to move near-term revenue materially. ACNP depression data
• Neutral Sentiment: Market attention / earnings on deck — J&J is widely searched and expected to report quarterly results next week, which can increase volatility as investors focus on guidance and MedTech/China commentary. Earnings expectations next week
• Negative Sentiment: Earnings-beat skepticism — a Zacks preview notes J&J “doesn’t possess the right combination” of factors that typically produce an earnings beat, implying upside to estimates may be limited and the stock could pull back if results or guidance disappoint. Zacks: odds of an earnings beat

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on JNJ shares. UBS Group reissued a “buy” rating on shares of Johnson & Johnson in a research note on Monday, January 5th. BMO Capital Markets reiterated an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, December 11th. Guggenheim raised their target price on shares of Johnson & Johnson from $206.00 to $227.00 and gave the stock a “buy” rating in a report on Friday, December 5th. Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Finally, Loop Capital set a $190.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 22nd. Four research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $213.33.

Johnson & Johnson Stock Up 2.3%

The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The stock has a market capitalization of $526.51 billion, a PE ratio of 21.09, a PEG ratio of 2.15 and a beta of 0.34. The company has a 50 day moving average price of $203.88 and a 200-day moving average price of $185.81.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 14th. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.76 by $0.04. The business had revenue of $23.99 billion for the quarter, compared to analysts’ expectations of $23.73 billion. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.42 earnings per share. As a group, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.4%. Johnson & Johnson’s payout ratio is presently 50.19%.

Institutional Trading of Johnson & Johnson

Several institutional investors and hedge funds have recently bought and sold shares of JNJ. Trust Co. of Oklahoma grew its holdings in shares of Johnson & Johnson by 3.5% during the 4th quarter. Trust Co. of Oklahoma now owns 3,468 shares of the company’s stock worth $718,000 after acquiring an additional 116 shares during the period. Centennial Wealth Advisory LLC lifted its stake in shares of Johnson & Johnson by 2.2% in the 4th quarter. Centennial Wealth Advisory LLC now owns 2,284 shares of the company’s stock valued at $473,000 after purchasing an additional 49 shares during the period. ORG Partners LLC boosted its position in shares of Johnson & Johnson by 6.9% during the fourth quarter. ORG Partners LLC now owns 11,334 shares of the company’s stock valued at $2,346,000 after purchasing an additional 728 shares in the last quarter. ORG Wealth Partners LLC grew its stake in Johnson & Johnson by 38.2% in the fourth quarter. ORG Wealth Partners LLC now owns 6,976 shares of the company’s stock worth $1,444,000 after purchasing an additional 1,930 shares during the period. Finally, Catalyst Private Wealth LLC raised its holdings in Johnson & Johnson by 3.2% in the fourth quarter. Catalyst Private Wealth LLC now owns 2,339 shares of the company’s stock worth $484,000 after purchasing an additional 72 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.